Patterson Companies (PDCO)
(Real Time Quote from BATS)
$21.10 USD
-0.83 (-3.79%)
Updated Sep 5, 2024 03:55 PM ET
After-Market: $21.10 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.10 USD
-0.83 (-3.79%)
Updated Sep 5, 2024 03:55 PM ET
After-Market: $21.10 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Zacks News
Dental Space Gains Momentum in 2021: 4 Stocks to Invest in
by Debanjana Dey
Dental stocks like Henry Schein (HSIC), Align Technology (ALGN), Straumann Holding (SAUHF) and DENTSPLY SIRONA (XRAY) are expected to continue their run over the next few months.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
PDCO, SABR, JRSH, UPWK, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2021
New Strong Sell Stocks for June 30th
by Zacks Equity Research
CLPR, HEXO, JRSH, MSEX and PDCO have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2021.
Company News for Jun 24, 2021
by Zacks Equity Research
Companies in The News Are: PDCO,GSK,SHAK,SON
Patterson Companies (PDCO) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2021 results benefit from strong segmental performance.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
Patterson Cos. (PDCO) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patterson Companies' (PDCO) Unit Completes Miller Vet Buyout
by Zacks Equity Research
Patterson Companies' (PDCO) subsidiary completes acquisition of Miller Vet, which is likely to bolster its Animal Health's presence in the companion animal market.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.
Henry Schein (HSIC) Software Module to Enhance Patient Outcome
by Zacks Equity Research
Henry Schein's (HSIC) latest software module is expected to provide better patient care and improved patient experience.
Patterson Companies (PDCO) Soars 6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Patterson Companies (PDCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Patterson Cos. (PDCO)
by Zacks Equity Research
Patterson Cos. (PDCO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Patterson Cos. (PDCO) Up 9.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Patterson Cos. (PDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and robust product portfolio. However, high debt level remains a woe.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Patterson Companies (PDCO) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2021 results benefit from strong segmental performance.
Patterson Cos. (PDCO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 13.73% and 4.12%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) patient volumes are expected to have increased significantly in the fourth quarter due to pent-up demand.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.
What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.